Description: Immutep Limited, a biotechnology company, engages in the research, development, and commercialization of biological products. The company develops immunotherapeutic products for the treatment of cancer and autoimmune diseases. Its therapeutics are based on the lymphocyte activation gene-3 (LAG-3) Ig fusion protein, a cell surface molecule that plays a role in regulating T cells. The company's lead product candidate is eftilagimod alpha (efti), which is in a Phase II and Phase I clinical trials for the treatment of metastatic breast cancer and solid tumors. Its other products include TACTI-002, a combination of efti with KEYTRUDA that is in a Phase II clinical trial for solid tumors; INSIGHT-004, a human anti-PD-L1 antibody, which is in a Phase I clinical trial to evaluate a combination of efti with avelumab; and TACTI-mel that is in a Phase I clinical trial for metastatic melanoma. The company also develops IMP701 for cancer; and IMP731 and IMP761 for autoimmune disease. Immutep Limited has partnerships with GlaxoSmithKline, Novartis, CYTLIMIC, INSIGHT, and EOC Pharma. The company was formerly known as Prima BioMed Ltd and changed its name to Immutep Limited in November 2017. Immutep Limited was incorporated in 1987 and is headquartered in Sydney, Australia.
Home Page: www.immutep.com
Australia Square
Sydney,
NSW
2000
Australia
Phone:
61 2 8315 7003
Officers
| Name | Title |
|---|---|
| Mr. Marc Voigt | CEO, MD, CFO, Chief Bus. Officer & Exec. Director |
| Ms. Deanne Miller LLB | COO, Gen. Counsel & Joint Company Sec. |
| Dr. Frederic Triebel M.D., Ph.D. | Chief Scientific Officer, Chief Medical Officer & Exec. Director |
| Ms. Indira Naidu | Joint Company Sec. |
| Mr. Christian Mueller | Director of Clinical Devel. & Regulatory Affairs |
| Mr. Shengfei Fang | Fin. Director & Assistant Company Sec. |
Exchange: PINK
Country: US
Currency: US Dollar ($)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 2.8102 |
| Price-to-Sales TTM: | 33.1172 |
| IPO Date: | |
| Fiscal Year End: | June |
| Full Time Employees: | 0 |